Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms

Pharmacogenetics

Volumn 11, Issue 3, 2001, Pages 207-215

  Fretland, A J ^a   Leff, M A ^a   Doll, M A ^a   Hein, D W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Acetylator genotype; N acetyltransferase; NAT2; Single nucleotide polymorphisms

Indexed keywords

2 FLUORENYLAMINE; ACYLTRANSFERASE; ADENINE; CARCINOGEN; CYTOSINE; GUANINE; MESSENGER RNA; NUCLEOTIDE; SULFADIMIDINE; THYMINE;

ACETYLATION; ACETYLATOR PHENOTYPE; ALLELE; ARTICLE; CATALYSIS; DRUG ACTIVATION; ENZYME ACTIVITY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; SCHIZOSACCHAROMYCES POMBE; SINGLE NUCLEOTIDE POLYMORPHISM;

ARYLAMINE N-ACETYLTRANSFERASE; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; BLOTTING, WESTERN; GENE EXPRESSION; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; SCHIZOSACCHAROMYCES; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; SULFAMETHAZINE;

EID: 0035052559     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200104000-00004     Document Type: Article

References (31)

1. The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in a Japanese population
2. Molecular mechanism of slow acetylation of drugs and carcinogens in humans
3. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: Correlation with phenotypic activity
4. NAT2* 12A (803A→G) codes for rapid arylamine N-acetylation in humans
5. Genomic sequencing
6. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver
7. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver
8. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2: Functional analysis of NAT1/NAT2 protein chimeras expressed in E. coli
9. 341/803) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles
10. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver
11. Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes
12. Human acetyltransferase polymorphisms
13. Distribution and concordance of Nacetyltransferase genotype and phenotype in an American population
14. NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cre
15. Molecular genetics of human polymorphic N-acetyltransferase: Enzymatic analysis of 15 recombinant wild-type, variant, and chimeric NAT2 allozymes
16. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specific NAT2 nucleic substitutions
17. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms
18. Update on consensus arylamine N-acetyltransferase gene nomenclature
19. Enzymatic kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli
20. N-acetyltransferase-2 polymorphism, smoking, and type 1 diabetic nephropathy
21. Post-transcriptional regulation of human microsomal epoxide hydrolase
22. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse
23. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype
24. Suggestions for the nomenclature of human alleles: Relevance to ecogenetics, pharmacogenetics and molecular epidemiology
25. Acetylator phenotype and genotype in patients infected with HIV: Discordance between methods for phenotype determination and genotype
26. Single-nucleotide polymorphisms can cause different structural folds of mRNA
27. N-acetyltransferases: Pharmacogenetics and clinical consequences of polymorphic drug acetylation
28. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by variant alleles in humans (TPMT* 3A, TPMT* 2): Mechanisms for the genetic polymorphism of TPMT activity
29. N-acetylation pharmacogenetics